Vital

Peptides

MOTS-c vs SS-31 vs NAD+: Evidence and FDA Status

MOTS-c vs SS-31 vs NAD+ injections: what each compound is, the human evidence, the FDA status of elamipretide, and why evidence levels differ so much.

Last reviewed

The Vital angle

Vital's peptide directory tags each compound with an evidence level (Extensive, Well Researched, Emerging, or Limited Data) and an FDA status such as Approved, a trial phase, Not approved, or Safety risk. You can filter the directory by both, so you can see at a glance how much human evidence sits behind a compound before you talk with a clinician. The directory is for reference, not medical advice.

MOTS-c vs SS-31: why people compare them

MOTS-c vs SS-31 is a common comparison in wellness and longevity circles, often with NAD+ injections in the same conversation. All three are marketed as ways to support mitochondria, the parts of a cell that make most of its energy. They are very different compounds, and the human evidence behind each one is very different.

This guide compares what each compound is, what studies in people show, and where each stands with the FDA. It does not recommend any compound, dose, schedule, or protocol. If you are thinking about any of them, talk with a clinician who knows your full medication list, including a GLP-1 medication if you take one. For combinations, see stacking peptides with a GLP-1.

The short answer

  1. SS-31 (elamipretide) has the most human data of the three. One product has an FDA accelerated approval for a single rare disease. A large phase 3 trial in a different disease did not meet its main goals.
  2. MOTS-c has mostly cell and animal data. The FDA reported no human exposure data for MOTS-c itself. It is not an approved drug.
  3. NAD+ is a coenzyme, not a peptide. Injected or intravenous NAD+ has very small human studies of how the body handles it, and no outcome trials for wellness or aging. It is not an FDA-approved drug for those uses.

What MOTS-c is and the evidence

MOTS-c is a short peptide encoded in mitochondrial DNA. Researchers described it in 2015. In cell and mouse studies, it acted on pathways linked to how cells use glucose and respond to exercise. Those findings are the basis for the claims about weight, insulin sensitivity, and endurance that sellers make.

Human data are thin. A company tested a synthetic analog called CB4211 in a small early trial in people with obesity and fatty liver. The company announced results in a press release, but no peer-reviewed paper reported them, and the program stopped when the company shut down. An analog is also a different molecule from native MOTS-c.

MOTS-c is not an FDA-approved drug. On the FDA compounding page current as of April 22, 2026, MOTS-c is in a table of withdrawn nominations, and the FDA notes that it found no human exposure data. In July 2026, an FDA advisory committee voted 7 to 5, with 2 abstentions, to recommend MOTS-c for the list of bulk substances that compounders may use. That vote is not binding, it is not an approval, and it is not a finding of safety. The FDA still has to decide and complete rulemaking.

What SS-31 (elamipretide) is and the evidence

SS-31 is a small peptide that goes into the inner membrane of mitochondria and binds cardiolipin, a fat that helps hold the energy machinery together. Its drug name is elamipretide.

In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. Barth syndrome is an ultra-rare genetic disease. The approval rests on a small crossover trial of 12 patients. That trial did not improve its main goals of walking distance and fatigue, and the approval used knee muscle strength instead. Accelerated approval requires a confirmatory trial to show real benefit to patients, and the FDA can withdraw it.

In primary mitochondrial myopathy, the phase 3 MMPOWER-3 trial randomized 218 people to elamipretide or placebo for 24 weeks. It did not meet its main goals for walking distance or fatigue. The drug was generally well tolerated, and a subgroup analysis led to a newer trial.

Two points matter for anyone who sees SS-31 for sale:

  1. The approval covers one product, for one disease, in one group of patients. It is not an approval for energy, aging, or weight.
  2. "SS-31" sold as a research chemical is not the approved product. Its content, purity, and sterility are not controlled the same way.

What NAD+ injections are and the evidence

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that every cell uses in energy reactions. Levels fall with age in some tissues, which led to interest in raising them with oral precursors, intravenous infusions, or injections.

The main pharmacokinetic study of intravenous NAD+ was a 2019 pilot in 11 healthy men, 8 of whom got NAD+. Plasma NAD+ and its breakdown products did not change for the first two hours of a six-hour infusion, so the body removed the infused NAD+ from the blood quickly. The study measured blood and urine levels only, not any health outcome. A 2026 narrative review found that the human evidence for intravenous NAD+ is sparse. It comes mostly from small uncontrolled studies, observational reports, and case reports, and data on long-term safety are limited.

NAD+ infusions and injections are offered by wellness clinics, but they are not FDA-approved drugs for aging, energy, or weight. Oral precursors such as nicotinamide riboside are sold as supplements, and supplements do not go through FDA drug approval.

How evidence levels differ

A useful way to compare compounds is to ask what kind of evidence exists, not how many articles mention them. Vital's peptide directory uses four evidence levels, and the same questions apply to any source:

  1. Extensive: many large human trials and an FDA label, as with semaglutide.
  2. Well Researched: randomized human trials, but fewer or smaller, or mixed results.
  3. Emerging: small human studies, often short, with early or surrogate measures.
  4. Limited Data: mostly cell or animal studies, case reports, or seller claims.

Approval status is a separate question. A compound can have human trials and no approval, or an approval for one narrow use only. For how to check a seller's claims against public sources, see peptide catalog source checks.

Questions to ask before you consider any of them

Use these questions with a clinician or pharmacist:

  1. Is this compound an approved drug, and for which condition?
  2. What human trials exist, how large were they, and did they meet their main goals?
  3. Who makes the product, and is there a certificate of analysis from a third-party lab?
  4. How does it interact with my other medications, including a GLP-1?
  5. What warning signs mean I need to stop and get care?
  6. How will we check whether it does anything for me?

Keep a written record of each product, lot number, start date, and any symptoms. The peptide half-life guide explains why half-life figures for research peptides are often unknown.

When to get medical help

Injected products from unregulated sources can carry contamination and dose errors. Get medical care right away for any of these signs:

  1. A hot, red, spreading, or very painful injection site, or pus.
  2. Fever or chills after an injection.
  3. Chest pain, a racing or irregular heartbeat, or fainting.
  4. Severe headache, vision changes, or new confusion.

Get emergency care for swelling of the face, lips, tongue, or throat, hives with trouble breathing, or trouble breathing of any kind. For milder skin reactions, see peptide injection site reaction.


Forzinity™ is a trademark of its respective owner. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • "SS-31" sold as a research chemical

    The FDA accelerated approval covers one elamipretide product for muscle strength in Barth syndrome. Research-chemical SS-31 is not that product, and its content, purity, and sterility are not controlled the same way.

  • MOTS-c claims based on mouse studies

    MOTS-c is not an FDA-approved drug, and the FDA reported no human exposure data for it. Weight and endurance claims come mostly from cell and animal research.

  • Treating an advisory committee vote as approval

    The July 2026 FDA advisory committee vote on MOTS-c for compounding is not binding and is not an approval or a finding of safety. The FDA still has to decide and complete rulemaking.

  • NAD+ infusions marketed for aging or energy

    Human pharmacokinetic data for intravenous NAD+ come from very small studies, and a 2026 review found the human evidence sparse and mostly uncontrolled. These infusions are not FDA-approved drugs for those uses.

  • Combining mitochondrial products with a GLP-1 without review

    Interactions between these compounds and GLP-1 medications are not studied. Tell your prescriber about every product you use.

Frequently asked questions

  • MOTS-c is a peptide encoded in mitochondrial DNA with mostly cell and animal data. SS-31, or elamipretide, binds cardiolipin in the mitochondrial membrane and has phase 2 and phase 3 human trials, plus one narrow FDA accelerated approval.

  • One product, Forzinity, received FDA accelerated approval in September 2025 to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is required. It is not approved for any other use.

  • No. MOTS-c is not an approved drug, and the FDA reported no human exposure data for it. A July 2026 advisory committee vote to recommend it for compounding is not binding and is not an approval.

  • The evidence is limited. The main intravenous study was a small 2019 pilot that measured blood and urine levels, not health outcomes. A 2026 review found the human evidence for intravenous NAD+ sparse, mostly from small uncontrolled studies.

  • No. NAD+ is a coenzyme made from a vitamin B3 base. It is often sold next to peptides, but it is a different kind of molecule.

  • Interactions are not studied. Tell your prescriber about every product, including the source and lot number, before you start anything new.

Sources

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  2. FDA Panel Backs 6 Peptides for Compounding · AJMC
  3. Elamipretide: First Approval · NIH / PubMed
  4. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial · NIH / NCBI
  5. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ · NIH / NCBI
  6. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine · NIH / NCBI

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.